Application of the solubility parameter concept to assist with oral delivery of poorly water-soluble drugs - a PEARRL review.


Journal

The Journal of pharmacy and pharmacology
ISSN: 2042-7158
Titre abrégé: J Pharm Pharmacol
Pays: England
ID NLM: 0376363

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 21 02 2018
accepted: 28 05 2018
pubmed: 7 7 2018
medline: 26 4 2019
entrez: 7 7 2018
Statut: ppublish

Résumé

Solubility parameters have been used for decades in various scientific fields including pharmaceutics. It is, however, still a field of active research both on a conceptual and experimental level. This work addresses the need to review solubility parameter applications in pharmaceutics of poorly water-soluble drugs. An overview of the different experimental and calculation methods to determine solubility parameters is provided, which covers from classical to modern approaches. In the pharmaceutical field, solubility parameters are primarily used to guide organic solvent selection, cocrystals and salt screening, lipid-based delivery, solid dispersions and nano- or microparticulate drug delivery systems. Solubility parameters have been applied for a quantitative assessment of mixtures, or they are simply used to rank excipients for a given drug. In particular, partial solubility parameters hold great promise for aiding the development of poorly soluble drug delivery systems. This is particularly true in early-stage development, where compound availability and resources are limited. The experimental determination of solubility parameters has its merits despite being rather labour-intensive because further data can be used to continuously improve in silico predictions. Such improvements will ensure that solubility parameters will also in future guide scientists in finding suitable drug formulations.

Identifiants

pubmed: 29978475
doi: 10.1111/jphp.12948
doi:

Substances chimiques

Excipients 0
Lipids 0
Pharmaceutical Preparations 0
Solvents 0
Water 059QF0KO0R

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

441-463

Subventions

Organisme : European Union's Horizon 2020 Research and Innovation Programme
ID : 674909

Informations de copyright

© 2018 Royal Pharmaceutical Society.

Auteurs

Sandra Jankovic (S)

Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland.

Georgia Tsakiridou (G)

Pharmathen SA, Product Design & Evaluation, Athens, Greece.
Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.

Felix Ditzinger (F)

Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland.

Niklas J Koehl (NJ)

School of Pharmacy, University College Cork, Cork, Ireland.

Daniel J Price (DJ)

Merck Group, Molecule Characterisation, Darmstadt, Germany.
Goethe University, Frankfurt, Germany.

Alexandra-Roxana Ilie (AR)

School of Pharmacy, University College Cork, Cork, Ireland.
Drug Product Development, Janssen Research and Development, Johnson & Johnson, Beerse, Belgium.

Lida Kalantzi (L)

Pharmathen SA, Product Design & Evaluation, Athens, Greece.

Kristof Kimpe (K)

Pharmaceutical Sciences, Janssen Research and Development, Johnson & Johnson, Beerse, Belgium.

René Holm (R)

Drug Product Development, Janssen Research and Development, Johnson & Johnson, Beerse, Belgium.

Anita Nair (A)

Merck Group, Molecule Characterisation, Darmstadt, Germany.

Brendan Griffin (B)

School of Pharmacy, University College Cork, Cork, Ireland.

Christoph Saal (C)

Merck Group, Molecule Characterisation, Darmstadt, Germany.

Martin Kuentz (M)

Institute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH